9/12/2023 0 Comments 4d molecular therapeutics salaryFactors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act. These forward-looking statements include, but are not limited to, statements about: In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Unregistered Sales of Equity Securities and Use of Proceeds Quantitative and Qualitative Disclosures About Market Risk Management’s Discussion and Analysis of Financial Condition and Results of Operations Notes to Unaudited Condensed Financial Statements Yes ☐ No ☒Īs of November 2, 2022, there were 32,392,378 shares of 4D Molecular Therapeutics, Inc.'s common stock outstanding.Ĭondensed Balance Sheets as of Septemand December 31, 2021Ĭondensed Statements of Operations for the Three and Nine Months Ended Septemand 2021Ĭondensed Statements of Comprehensive Loss for the Three and Nine Months Ended Septemand 2021Ĭondensed Statements of Stockholders’ Equity for the Three and Nine Months Ended Septemand 2021Ĭondensed Statements of Cash Flows for the Nine Months Ended Septemand 2021 Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Name of each exchange on which registeredĬommon Stock, par value $0.0001 per share Securities registered pursuant to Section 12(b) of the Act: Registrant’s telephone number, including area code: (510) 505-2680 (Exact name of registrant as specified in its charter) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO. QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934įor the quarterly period ended September 30, 2022
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |